EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Fulcrum Therapeutics, Inc. (FULC) EBITDA Margin data is not available for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-74.88M |
|
-- |
|
-- |
|
$84.77M |
|
$-84.77M |
|
$9.89M |
|
$-74.88M |
|
$-74.88M |
|
$-74.88M |
|
$-74.88M |
|
$-74.88M |
|
$-74.88M |
|
$-84.77M |
|
$-83.38M |
|
63.35M |
|
63.35M |
|
$-1.18 |
|
$-1.18 |
|
| Balance Sheet Financials | |
$357.48M |
|
$2.82M |
|
$8.80M |
|
$366.28M |
|
$13.05M |
|
-- |
|
$4.24M |
|
$17.28M |
|
$349.00M |
|
$349.00M |
|
$349.00M |
|
66.58M |
|
| Cash Flow Statement Financials | |
$-60.06M |
|
$30.72M |
|
$168.67M |
|
$59.41M |
|
$198.73M |
|
$139.32M |
|
$12.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
27.40 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
EBITDA Margin |
-- |
-- |
|
-- |
|
$-60.38M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.46% |
|
-21.46% |
|
-20.44% |
|
-21.46% |
|
$5.24 |
|
$-0.95 |
|
$-0.95 |
|